← Back to Clinical Trials
Recruiting NCT06580964

NCT06580964 Heat and Exercise in Aging as Therapy (HEAT)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06580964
Status Recruiting
Phase
Sponsor Texas Tech University
Condition Prediabetic State
Study Type INTERVENTIONAL
Enrollment 54 participants
Start Date 2025-07-31
Primary Completion 2028-07

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Heat therapyHigh-intensity interval training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 54 participants in total. It began in 2025-07-31 with a primary completion date of 2028-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main goal of this two-phase clinical trial is to learn whether local heat therapy, using heat pads applied to the legs, can enhance skeletal muscle health, physical function, and blood sugar control in a manner comparable to exercise, specifically High-Intensity Interval Training (HIIT), in older individuals with prediabetes. The study aims to answer the following questions: 1. Does local heat therapy improve muscle architecture (e.g., muscle cross-sectional area, capillary density, mitochondrial content), glucose tolerance, and frailty indicators similarly to HIIT in older individuals with prediabetes? 2. Does local heat therapy as a pre-conditioning method enhance the skeletal muscle response to HIIT in older individuals with prediabetes?

Eligibility Criteria

Inclusion Criteria: * Age ≥ 50 years * Women who are postmenopausal, defined as no menstrual period for at least 12 consecutive months. * Sedentary (structured exercise \<30 minutes, 3x/week) * Body weight is at least 110 lbs * Meet criteria for prediabetes (fasting blood glucose 100-125 mg/dl, hemoglobin A1c 5.7-6.4%) * Consume \<8 (women) or \<15 (men) alcohol-containing beverages per week * Do not use nicotine or cannabis * Not taking any medications that could interfere with responses to the interventions (e.g., corticosteroids, opiates, benzodiazepines, tricyclic antidepressants, beta blockers, sulfonylureas, insulin, metformin, anticoagulants, barbiturates, insulin sensitizers, fibrates, immunosuppressants). If you don't know, that's okay. We'll ask what medications you are on and check whether they fall into one of these categories. Exclusion Criteria: * History of peripheral neuropathies * Currently taking prescription blood thinners * Medical complications that could would contraindicate participation in the high intensity interval training (HIIT) intervention including: orthopedic complications that would limit your ability to perform cycling exercise, significant cardiovascular impairments (e.g., history of arrhythmias, severe uncontrolled hypertension, etc.), diagnosed metabolic disease (e.g., diabetes), renal disease, sickle cell anemia, or cancer in remission for \<6 months. * Known history of slow wound healing * Lidocaine allergy * Latex allergy * Currently pregnant * \>1.5" subcutaneous fat over the thigh muscle * Symptoms suggestive of cardiovascular, respiratory, metabolic, or renal diseases including discomfort, pressure, or pain in your chest, neck, jaw, arms, calves, or other areas potentially related to ischemia; shortness of breath at rest or with mild exertion; dizziness or fainting (syncope); difficulty breathing while lying flat (orthopnea) or sudden nighttime breathing difficulties (paroxysmal nocturnal dyspnea); palpitations or rapid heartbeat (tachycardia); pain or cramping in your legs during physical activity (intermittent claudication); a known heart murmur; swelling in your ankles (edema); unusual fatigue or shortness of breath during routine activities or at rest.

Contact & Investigator

Central Contact

Hui-Ying Luk, PhD

✉ huiying.luk@ttu.edu

📞 8068340827

Principal Investigator

Hui-Ying Luk, PhD; Danielle Levitt, PhD

PRINCIPAL INVESTIGATOR

Texas Tech University

Frequently Asked Questions

Who can join the NCT06580964 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Prediabetic State. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06580964 currently recruiting?

Yes, NCT06580964 is actively recruiting participants. Contact the research team at huiying.luk@ttu.edu for enrollment information.

Where is the NCT06580964 trial being conducted?

This trial is being conducted at Lubbock, United States.

Who is sponsoring the NCT06580964 clinical trial?

NCT06580964 is sponsored by Texas Tech University. The principal investigator is Hui-Ying Luk, PhD; Danielle Levitt, PhD at Texas Tech University. The trial plans to enroll 54 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology